Clinical relevance of pre- and coseasonal sublingual immunotherapy with a 300 index of reactivity 5-grass SLIT tablet in allergic rhinoconjunctivitis.
allergen immunotherapy
allergic rhinoconjunctivitis
clinical relevance
combined symptom and medication score
grass pollen tablet
Journal
Clinical and translational allergy
ISSN: 2045-7022
Titre abrégé: Clin Transl Allergy
Pays: England
ID NLM: 101576043
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
31
10
2023
received:
29
09
2023
accepted:
21
11
2023
medline:
26
12
2023
pubmed:
26
12
2023
entrez:
26
12
2023
Statut:
ppublish
Résumé
There is considerable interest in improving the scoring methods for evaluating the efficacy of allergen immunotherapy (AIT) and to show if this is associated with clinically meaningful results from the patient's perspective. We aimed to assess the efficacy and clinical relevance of a 300 index of reactivity (IR) 5-grass pollen sublingual immunotherapy (SLIT) tablet in children, adolescents and adults with moderate to severe grass-induced allergic rhinoconjunctivitis (ARC) with or without controlled asthma using the combined symptom and medication score CSMS The data of the European population that participated in 3 Phase III, international, randomized double-blind placebo-controlled clinical trials were analyzed post hoc. A total of 864 patients randomized to 300 IR 5-grass tablet or placebo were analyzed. Over the primary evaluation period, the difference in CSMS Post hoc analysis of 3 CTs with the 300 IR 5-grass SLIT tablet confirmed its significant and clinically relevant effect in the European population with grass pollen-induced ARC with or without controlled asthma.
Sections du résumé
BACKGROUND
BACKGROUND
There is considerable interest in improving the scoring methods for evaluating the efficacy of allergen immunotherapy (AIT) and to show if this is associated with clinically meaningful results from the patient's perspective. We aimed to assess the efficacy and clinical relevance of a 300 index of reactivity (IR) 5-grass pollen sublingual immunotherapy (SLIT) tablet in children, adolescents and adults with moderate to severe grass-induced allergic rhinoconjunctivitis (ARC) with or without controlled asthma using the combined symptom and medication score CSMS
METHODS
METHODS
The data of the European population that participated in 3 Phase III, international, randomized double-blind placebo-controlled clinical trials were analyzed post hoc.
RESULTS
RESULTS
A total of 864 patients randomized to 300 IR 5-grass tablet or placebo were analyzed. Over the primary evaluation period, the difference in CSMS
CONCLUSION
CONCLUSIONS
Post hoc analysis of 3 CTs with the 300 IR 5-grass SLIT tablet confirmed its significant and clinically relevant effect in the European population with grass pollen-induced ARC with or without controlled asthma.
Types de publication
Journal Article
Langues
eng
Pagination
e12321Subventions
Organisme : Stallergenes Greer
Informations de copyright
© 2023 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
Références
Pfaar O, Angier E, Muraro A, Halken S, Roberts G. Algorithms in allergen immunotherapy in allergic rhinoconjunctivitis. Allergy. 2020;75(9):2411-2414. https://doi.org/10.1111/all.14270
Roberts G, Pfaar O, Akdis CA, et al. EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis. Allergy. 2018;73(4):765-798. https://doi.org/10.1111/all.13317
Bousquet PJ, Bachert C, Canonica GW, et al. Uncontrolled allergic rhinitis during treatment and its impact on quality of life: a cluster randomized trial. J Allergy Clin Immunol. 2010;126(3):666-668.e661-665. https://doi.org/10.1016/j.jaci.2010.06.034
Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8-160. https://doi.org/10.1111/j.1398-9995.2007.01620.x
Pfaar O, Gerth van Wijk R, Klimek L, Bousquet J, Creticos PS. Clinical trials in allergen immunotherapy in the age group of children and adolescents: current concepts and future needs. Clin Transl Allergy. 2020;10(1):11. https://doi.org/10.1186/s13601-020-00314-1
Dhami S, Nurmatov U, Arasi S, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis. Allergy. 2017;72(11):1597-1631. https://doi.org/10.1111/all.13201
Jutel M, Agache I, Bonini S, et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol. 2015;136(3):556-568. https://doi.org/10.1016/j.jaci.2015.04.047
Pfaar O, Bousquet J, Durham SR, et al. One hundred and ten years of Allergen Immunotherapy: a journey from empiric observation to evidence. Allergy. 2022;77(2):454-468. https://doi.org/10.1111/all.15023
Muraro A, Roberts G, Halken S, et al. EAACI guidelines on allergen immunotherapy: executive statement. Allergy. 2018;73(4):739-743. https://doi.org/10.1111/all.13420
Pfaar O, Ankermann T, Augustin M, et al. Guideline on allergen immunotherapy in IgE-mediated allergic diseases. Allergol Sel. 2022;6(1):167-232. https://doi.org/10.5414/alx02331e
Didier A, Malling HJ, Worm M, Horak F, Sussman GL. Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score. Clin Transl Allergy. 2015;5(1):12. https://doi.org/10.1186/s13601-015-0057-8
Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;120(6):1338-1345. https://doi.org/10.1016/j.jaci.2007.07.046
Didier A, Worm M, Horak F, et al. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol. 2011;128(3):559-566. https://doi.org/10.1016/j.jaci.2011.06.022
Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2009;123(1):160-166.e163. https://doi.org/10.1016/j.jaci.2008.10.009
Pfaar O, Demoly P, Gerth van Wijk R, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014;69(7):854-867. https://doi.org/10.1111/all.12383
Committee for Medicinal Products for Human Use ICH guideline E17 on general principles for planning and design of multi-regional clinical trials. Step 5. (EMA/CHMP/ICH/453276/2016 Rev.1). In: European Medicines Agency; 2017.
Durham SR, Nelson HS, Nolte H, et al. Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure. Allergy. 2014;69(5):617-623. https://doi.org/10.1111/all.12373
Bousquet J, van Cauwenberge P. Allergic rhinitis and its impact on asthma (ARIA) in collaboration with the World Health Organisation. Prim Care Respir J. 2002;11(1):18-19. https://doi.org/10.1038/pcrj.2002.7
Grouin JM, Vicaut E, Jean-Alphonse S, et al. The average Adjusted Symptom Score, a new primary efficacy end-point for specific allergen immunotherapy trials. Clin Exp Allergy. 2011;41(9):1282-1288. https://doi.org/10.1111/j.1365-2222.2011.03700.x
Canonica GW, Baena-Cagnani CE, Bousquet J, et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy. 2007;62(3):317-324. https://doi.org/10.1111/j.1398-9995.2006.01312.x
Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129(3):717-725.e715. https://doi.org/10.1016/j.jaci.2011.12.973
GRASTEK®. MK-7743 timothy grass pollen extract tablets advisory committee meeting briefing document. 2013;12:2013. Accessed 29 September 2023. https://www.fda.gov/media/103470/download
Pfaar O, Alvaro M, Cardona V, Hamelmann E, Mosges R, Kleine-Tebbe J. Clinical trials in allergen immunotherapy: current concepts and future needs. Allergy. 2018;73(9):1775-1783. https://doi.org/10.1111/all.13429
Didier A, Melac M, Montagut A, Lheritier-Barrand M, Tabar A, Worm M. Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy. Allergy. 2009;64(1):166-171. https://doi.org/10.1111/j.1398-9995.2008.01767.x
Halken S, Agertoft L, Seidenberg J, et al. Five-grass pollen 300IR SLIT tablets: efficacy and safety in children and adolescents. Pediatr Allergy Immunol. 2010;21(6):970-976. https://doi.org/10.1111/j.1399-3038.2010.01050.x
Klein TM, Hadler M, Augustin M, Blome C. Patient needs and benefits of sublingual immunotherapy for grass pollen-induced allergic rhinitis: an observational study. Immunotherapy. 2021;13(14):1193-1204. https://doi.org/10.2217/imt-2021-0161
Spriggs K, Pfaar O, Pawankar R, Durham S. Is “maintenance” a misnomer? A narrative framework setting the right expectations of allergen immunotherapy. J Allergy Clin Immunol Pract. 2023;11(7):2051-2053. https://doi.org/10.1016/j.jaip.2023.02.033
Incorvaia C, Ridolo E, Bagnasco D, Scurati S, Canonica GW. Personalized medicine and allergen immunotherapy: the beginning of a new era? Clin Mol Allergy. 2021;19(1):10. https://doi.org/10.1186/s12948-021-00150-z
Demoly P, Calderon MA, Casale TB, Malling HJ, Wahn U. The value of pre- and co-seasonal sublingual immunotherapy in pollen-induced allergic rhinoconjunctivitis. Clin Transl Allergy. 2015;5(1):18. https://doi.org/10.1186/s13601-015-0061-z
Cox LS, Casale TB, Nayak AS, et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. J allergy Clin Immunol. 2012;130(6):1327-1334.e1321. https://doi.org/10.1016/j.jaci.2012.08.032
Demoly P, Corren J, Creticos P, et al. A 300 IR sublingual tablet is an effective, safe treatment for house dust mite-induced allergic rhinitis: an international, double-blind, placebo-controlled, randomized phase III clinical trial. J Allergy Clin Immunol. 2021;147(3):1020-1030.e1010. https://doi.org/10.1016/j.jaci.2020.07.036
Pfaar O, Bachert C, Kuna P, et al. Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma. J Allergy Clin Immunol. 2019;143(3):970-977. https://doi.org/10.1016/j.jaci.2018.11.018
Worm M, Rak S, de Blay F, et al. Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled study. Clin Transl Allergy. 2014;4(1):7. https://doi.org/10.1186/2045-7022-4-7
Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61(2):102-109. https://doi.org/10.1016/j.jclinepi.2007.03.012
Pfaar O, Agache I, de Blay F, et al. Perspectives in allergen immunotherapy: 2019 and beyond. Allergy. 2019;74(Suppl 108):3-25. https://doi.org/10.1111/all.14077